It was wonderful to see the CU School of Medicine’s RNA Bioscience Initiative (RBI) featured at last week’s Transforming Healthcare event. Presented by Chancellor Elliman, this community lecture series showcases the extraordinary medical advancements and scientific progress taking place on our campus.
The RBI team shared how their breakthroughs are transforming the future of medicine, opening up a wide range of new treatments, diagnostic tools and therapies. If you weren’t able to make it to the April 26 event, I would encourage you to watch a recording online, including all five speakers’ presentations.
I want to recognize the RBI team and all those involved in organizing this very successful event spotlighting the outstanding basic science research taking place on the CU Anschutz Medical Campus.
Thomas Flaig, MD
Vice Chancellor for Research
University of Colorado Denver | Anschutz
To submit a proposal for these opportunities:
Interested candidates must send a one-page summary of their research proposal and their biosketch in pdf format via the Limited Submission Portal.
An eligible institution may submit a maximum of two proposals (e.g., 2 RED Innovation Track or 1 RED A&I Track and 1 RED Two-year Track)
Fiscal Year 2022 (FY22) funding opportunities and pre-announcements for the Department of Defense (DoD) programs managed by the office of Congressionally Directed Medical Research Programs (CDMRP) are below.
CDMRP understands that applicants continue to be impacted by COVID-19. Submission deadlines for pre-applications and full applications will incorporate the maximum time that is feasible for each FY22 program.
Breast Cancer Research Program (BCRP) - Pre-application Submission deadline is May 3, 2022 5pm EST for the following FY22 BCRP funding opportunities:
As part of the RECOVER Initiative, the NIH is soliciting applications for clinical trials in individuals over 18 years old for the prevention and/or treatment of PASC.
The NIH is seeking proposals for clinical trials testing a range of interventions and using diverse methods to address symptoms/symptom clusters and the underlying mechanisms of the pathobiology of PASC.
Trial proposals should reflect community and patient engagement. The funding will utilize the NIH's Other Transaction Authority (OTA).
A technical assistance webinar is anticipated tentatively for May 6, 2022. Please check back on the RECOVER funding page and on the NIH funding announcement website for additional information and the registration link.
For additional information please email NHLBI_OTA@mail.nih.gov.
Applicants from any U.S. academic institution that serves children and youth with special health care needs may apply.
Preference is given to those proposals that have the potential to lead to projects of a larger and longer-term nature.
A family or youth partner is required. Up to three projects focused on health systems research for children and youth with special health care needs will be funded up to $15,000 (1-year).
The Cancer Center is now accepting applications for K12 Scholar appointments to the Paul Calabresi Award for Clinical Oncology Research (PCACOR).
The purpose of the PCACOR is to prepare highly qualified cancer clinical researchers called Paul Calabresi Clinical Oncology Research Scholars (Scholars) who can independently design, manage and complete cancer clinical trials.
Scholars learn to communicate and coordinate with multidisciplinary teams of clinical and basic/behavioral research scientists to test rational hypotheses and manage all phases of cancer clinical trials using state-of-the-art laboratory analyses to personalize cancer treatment.
The K12 provides $100,000 in salary support and $30,000 for Research and Development (R&D) per year. Scholars are guaranteed 2 years of support.
For additional information, please contact Paige Diller.
This bulletin is distributed on the 1st & 3rd Tuesday of the month for the CU Anschutz Research Community.